Memorial Şişli Hospital
Prof. Hüseyin Baloğlu is a pathology specialist at Anadolu Medical Center in Gebze, Kocaeli, Turkey. He focuses on molecular pathology, surgical pathology, and tumour biopsy and diagnostics.
Education and accreditations: MD, GATA Medical School (1986). Pathology specialty training, GATA (1992). Associate Professor (Doçent), GATA (2004). Visiting scholar at Albert Einstein College of Medicine (New York) and Heidelberg University.
Achievements: author of over 600 peer‑reviewed publications. Holds a patent in molecular diagnostics for thyroid cancer. Leads liquid biopsy and precision oncology services.
Professor of Medical Oncology with a focus on Gastrointestinal Oncology – Prof. Sağlam brings specialized expertise to IgG4 RD cases at Gayrettepe Florence Nightingale Hospital.
Prof. Dr. Sefik Igdem specializes in advanced radiation oncology at Gayrettepe Florence Nightingale Hospital.
Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).
He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.
Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.
Standard treatment for IgG4-Related Disease in Turkey primarily involves long-term corticosteroid therapy to induce remission. Specialists commonly prescribe prednisolone at starting doses of 30–40 mg/day. Turkish oncology and rheumatology centers utilize rituximab for steroid-resistant cases or frequent relapses to maintain organ function.
Bookimed Expert Insight: Turkish JCI-accredited hospitals like Memorial Şişli and Medical Park Antalya often manage IgG4-RD through multidisciplinary oncology units. While standard protocols focus on steroids, these centers offer 512-slice CT and 3 Tesla MRI for precise relapse monitoring. This advanced diagnostic capacity helps distinguish the disease from cancer, a common challenge in complex cases.
Patient Consensus: Patients note that while symptoms resolve quickly with steroids, they often reappear during the tapering phase. Many emphasize the importance of early biopsy to prevent misdiagnosis as a tumor.
Turkish centers in Istanbul and Ankara manage IgG4-Related Disease using multidisciplinary teams of rheumatologists and pathologists. Facilities like Memorial Şişli Hospital and Hisar Hospital provide specialized diagnostics, including biopsy staining and systemic therapy. Key expertise includes advanced imaging and targeted treatment protocols.
Bookimed Expert Insight: While many seek oncology centers, the key differentiator for IgG4-RD in Turkey is pathology expertise. Prof. Hüseyin Baloglu has over 600 publications and specialized training at global institutions. His focus on surgical pathology and diagnostics is vital since this rare disease is easily misdiagnosed as cancer.
Patient Consensus: Patients emphasize finding tertiary hospitals where doctors recognize the disease as systemic rather than a single-organ issue. They often note that a definitive diagnosis depends entirely on having a pathologist experienced in specific IgG4 staining patterns.
IgG4-related disease requires long-term management because it is a chronic, relapsing condition. Initial steroid induction typically lasts 2 to 4 weeks. Clinicians then taper medication over 3 to 6 months. Patients often undergo follow-up monitoring for 1.5 to 6 years to detect flares.
Bookimed Expert Insight: Turkish oncology and pathology centers like Anadolu Medical Center emphasize precise molecular diagnostics to distinguish IgG4-RD from malignancies. Since approximately 40% of patients relapse within 12 months, leading specialists often recommend utilizing clinics with multidisciplinary tumor boards to coordinate long-term immunosuppression safely.
Patient Consensus: Patients emphasize that treatment is rarely a one-time event and requires staying vigilant. They note that follow-up eventually shifts to less frequent check-ups and periodic imaging once the disease stabilizes.
Surgery is primarily used for diagnosis or managing severe complications like organ obstruction in Turkish hospitals. Surgeons perform biopsies to distinguish disease lesions from malignant tumors. Most patients achieve remission using corticosteroids or immunosuppressants without requiring major surgical intervention for disease management.
Bookimed Expert Insight: Turkish oncology centers like Memorial Sisli and Hisar Intercontinental often serve as diagnostic hubs because IgG4-RD mimics cancer on scans. Our data shows these facilities utilize high-resolution 3 Tesla MRI and PET/CT to minimize unnecessary surgeries by improving diagnostic accuracy before any invasive steps.
Patient Consensus: Patients note that surgery often happens because the disease looks exactly like a tumor on initial scans. Many emphasize requesting a biopsy first to see if medical treatment can replace a major operation.
Turkish specialists monitor IgG4-RD through serial serum IgG4 levels and inflammatory markers. JCI-accredited centers in Istanbul use 512-slice CT and 3 Tesla MRI for high-resolution imaging. Care plans are personalized using tailored steroid protocols and biological agents based on specific organ involvement.
Bookimed Expert Insight: Patient volume data shows Hisar Hospital Intercontinental serves 250,000 patients annually. Large centers like this typically offer faster diagnostic windows. Most international patients receive a full diagnostic workup within 3 to 7 days. This rapid turnaround is critical for IgG4-RD to prevent irreversible organ scarring.
Patient Consensus: Patients emphasize the need to bring original pathology slides for review. They note that follow-up remains intensive because the disease can relapse with no visible symptoms.